Navigation Links
Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
Date:9/6/2012

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced  today that at a General Meeting of its Stockholders held on September 5, 2012, Actinium's shareholders voted to approve all of the resolutions proposed by the Board of Directors. 

Shareholders authorized a raise of up to $25 million in new funds to be used for further clinical development of Actimab-A and Iomab-B, Actinium's clinical stage drug candidates for treatment of hematologic malignancies, and continued preclinical development of additional drug candidates in solid cancer indications as well as for general working purposes.  This funding round will be raised by Laidlaw & Company.

"This raise will allow us to continue our efforts in helping the patients suffering from serious forms of cancer for which there are currently very few options," said Jack Talley, Actinium's CEO.  "Our drug candidates have demonstrated significant potential in ongoing trials and we expect to continue ongoing work in treating elderly acute myeloid leukemia as well as enabling otherwise untreatable bone marrow transplantation."

In addition, the shareholders authorized a public listing for the Company's shares.  "In addition to providing liquidity for our investors, this transaction will increase the Company's profile in the marketplace as we pursue innovative therapies for various forms of cancer," commented Mr. Talley.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a Newark, New Jersey based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com

Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com  

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

 


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Strengthens Management Team
2. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
3. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
4. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
5. Global Markets for Membrane Technology for Pharmaceuticals
6. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
7. Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Womens Health Business to Meda
8. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
9. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
10. Questcor Pharmaceuticals to Present at Investor Conferences in September
11. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
Breaking Medicine Technology:
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance ... serves communities throughout southern Florida, is working to support the Take Stock In ... from low income families. , The Take Stock In Children Foundation (TSC) offers ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... The ... communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to ... husband. , In early June of this year, Christina and her children returned from ...
Breaking Medicine News(10 mins):